FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322758060> ?p ?o ?g. }

• W4322758060 endingPage "225" @default.
• W4322758060 startingPage "213" @default.
• W4322758060 abstract "Immunostimulatory cues play an important role in priming antitumor immunity and promoting the efficacy of subunit cancer vaccines. However, the clinical use of many immunostimulatory agents is often hampered by their inefficient in vivo delivery which may decrease immune response to the vaccination. To promote vaccine efficacy, we develop vaccine formulations which integrate three key elements: (1) a nano-adjuvant formulated by conjugating an agonistic anti-CD40 monoclonal antibody (αCD40) to the surface of a polyIC-loaded lipid nanoparticle, (2) a peptide amphiphile containing an optimized CD8+ T-cell epitope that derived from a melanoma antigen gp100, (3) an agonistic anti-4-1BB monoclonal antibody (α4-1BB) that boosts the efficacy of vaccinations. In a syngeneic mouse model of melanoma, the vaccine formulations enhanced innate immunity and activated multiple innate immune signaling pathways within draining lymph nodes, as well as promoted antigen-specific immune responses and reduced immunosuppression in the tumor microenvironment, leading to profound tumor growth inhibition and prolonged survival. Thus, our vaccine formulations represent an attractive strategy to stimulate antitumor immunity and control tumor progression. The clinical use of many immunostimulatory agents is often hampered by their inefficient in vivo delivery which may decrease immune response to the vaccination. To promote the antitumor immunity of subunit vaccines, we develop novel vaccine formulations that integrate multifunctional modalities including (1) a nano-adjuvant containing anti-CD40 monoclonal antibody (αCD40) and TLR3 agonist which activate innate immunity through diverse signaling pathways, (2) a peptide amphiphile containing an optimized CD8+ T-cell epitope from tumor antigen, (3) an anti-4-1BB monoclonal antibody (α4-1BB) that boosts the efficacy of vaccinations. In this study, our vaccine formulations stimulate superior antitumor immunity and control tumor progression. The above nano-engineered platform and immunogenic biomacromolecules can be further applied to other T-cell-inducing vaccines." @default.
• W4322758060 created "2023-03-03" @default.
• W4322758060 creator A5009587141 @default.
• W4322758060 creator A5022216026 @default.
• W4322758060 creator A5031767581 @default.
• W4322758060 creator A5043535101 @default.
• W4322758060 creator A5084554557 @default.
• W4322758060 date "2023-04-01" @default.
• W4322758060 modified "2023-10-18" @default.
• W4322758060 title "Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles" @default.
• W4322758060 cites W1010975229 @default.
• W4322758060 cites W1501518736 @default.
• W4322758060 cites W1512799118 @default.
• W4322758060 cites W1986126905 @default.
• W4322758060 cites W1986842655 @default.
• W4322758060 cites W1994942139 @default.
• W4322758060 cites W2012220965 @default.
• W4322758060 cites W2021218243 @default.
• W4322758060 cites W2030132644 @default.
• W4322758060 cites W2044568975 @default.
• W4322758060 cites W2047365750 @default.
• W4322758060 cites W2049309853 @default.
• W4322758060 cites W2054805106 @default.
• W4322758060 cites W2064229941 @default.
• W4322758060 cites W2064522385 @default.
• W4322758060 cites W2066911216 @default.
• W4322758060 cites W2073553356 @default.
• W4322758060 cites W2087604357 @default.
• W4322758060 cites W2097642851 @default.
• W4322758060 cites W2097845460 @default.
• W4322758060 cites W2098927214 @default.
• W4322758060 cites W2111551833 @default.
• W4322758060 cites W2119864130 @default.
• W4322758060 cites W2131371327 @default.
• W4322758060 cites W2142022669 @default.
• W4322758060 cites W2167028666 @default.
• W4322758060 cites W2254172772 @default.
• W4322758060 cites W2282980403 @default.
• W4322758060 cites W2418018584 @default.
• W4322758060 cites W2522054472 @default.
• W4322758060 cites W2617823945 @default.
• W4322758060 cites W2780310856 @default.
• W4322758060 cites W2795670954 @default.
• W4322758060 cites W2811117516 @default.
• W4322758060 cites W2886702901 @default.
• W4322758060 cites W2909781225 @default.
• W4322758060 cites W2943084404 @default.
• W4322758060 cites W2967833499 @default.
• W4322758060 cites W2970504186 @default.
• W4322758060 cites W2994744934 @default.
• W4322758060 cites W3003195528 @default.
• W4322758060 cites W3013673954 @default.
• W4322758060 cites W3043888380 @default.
• W4322758060 cites W3047822613 @default.
• W4322758060 cites W3087341228 @default.
• W4322758060 cites W3117859846 @default.
• W4322758060 cites W3118726031 @default.
• W4322758060 cites W3121346966 @default.
• W4322758060 cites W3127149665 @default.
• W4322758060 cites W3133680693 @default.
• W4322758060 cites W3135379629 @default.
• W4322758060 cites W3197519045 @default.
• W4322758060 cites W4229456682 @default.
• W4322758060 doi "https://doi.org/10.1016/j.actbio.2023.02.034" @default.
• W4322758060 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36858163" @default.
• W4322758060 hasPublicationYear "2023" @default.
• W4322758060 type Work @default.
• W4322758060 citedByCount "0" @default.
• W4322758060 crossrefType "journal-article" @default.
• W4322758060 hasAuthorship W4322758060A5009587141 @default.
• W4322758060 hasAuthorship W4322758060A5022216026 @default.
• W4322758060 hasAuthorship W4322758060A5031767581 @default.
• W4322758060 hasAuthorship W4322758060A5043535101 @default.
• W4322758060 hasAuthorship W4322758060A5084554557 @default.
• W4322758060 hasConcept C147483822 @default.
• W4322758060 hasConcept C195616568 @default.
• W4322758060 hasConcept C203014093 @default.
• W4322758060 hasConcept C22070199 @default.
• W4322758060 hasConcept C2777701055 @default.
• W4322758060 hasConcept C2777863537 @default.
• W4322758060 hasConcept C2779341262 @default.
• W4322758060 hasConcept C2780674031 @default.
• W4322758060 hasConcept C502942594 @default.
• W4322758060 hasConcept C86803240 @default.
• W4322758060 hasConcept C8891405 @default.
• W4322758060 hasConceptScore W4322758060C147483822 @default.
• W4322758060 hasConceptScore W4322758060C195616568 @default.
• W4322758060 hasConceptScore W4322758060C203014093 @default.
• W4322758060 hasConceptScore W4322758060C22070199 @default.
• W4322758060 hasConceptScore W4322758060C2777701055 @default.
• W4322758060 hasConceptScore W4322758060C2777863537 @default.
• W4322758060 hasConceptScore W4322758060C2779341262 @default.
• W4322758060 hasConceptScore W4322758060C2780674031 @default.
• W4322758060 hasConceptScore W4322758060C502942594 @default.
• W4322758060 hasConceptScore W4322758060C86803240 @default.
• W4322758060 hasConceptScore W4322758060C8891405 @default.
• W4322758060 hasFunder F4320321001 @default.
• W4322758060 hasFunder F4320323059 @default.

• next